{"id":63874,"date":"2026-11-10T14:41:45","date_gmt":"2026-11-10T14:41:45","guid":{"rendered":"https:\/\/ibima.eu\/?p=63874"},"modified":"2026-11-10T14:41:55","modified_gmt":"2026-11-10T14:41:55","slug":"spock-eu","status":"publish","type":"post","link":"https:\/\/ibima.eu\/es\/spock-eu\/","title":{"rendered":"SPOCK"},"content":{"rendered":"

[et_pb_section fb_built=\u00bb1″ _builder_version=\u00bb4.27.6″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb25px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_row _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_heading title=\u00bbStroke Pharmaco-Omics Consortium\u00bb _builder_version=\u00bb4.27.7″ _module_preset=\u00bbdefault\u00bb title_font=\u00bb||||||||\u00bb title_text_align=\u00bbcenter\u00bb title_text_color=\u00bb#0C71C3″ module_alignment=\u00bbcenter\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][\/et_pb_heading][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb2_3,1_3″ _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb30px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_column type=\u00bb2_3″ _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_text _builder_version=\u00bb4.27.7″ _module_preset=\u00bbdefault\u00bb hover_enabled=\u00bb0″ global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb sticky_enabled=\u00bb0″]<\/p>\n

\n
\n
\n
\n
\n
\n

Financed by<\/span><\/strong> : Consejer\u00eda de Presidencia, Sanidad y Emergencias de la Junta de Andaluc\u00eda<\/span><\/span><\/p>\n

Program<\/strong>: EP PerMed \u2013 Joint Transnational Call 2025 \u201cPharmacogenomic Strategies for Personalised Medicine Approaches (PGxPM2025)\u201d<\/a><\/span><\/p>\n

Project National Reference:<\/strong> <\/span>HOR-2026-07<\/em><\/p>\n

Role in the project:<\/strong> Partner<\/span><\/p>\n

Duration:<\/b> August 2026 to July 2029<\/span><\/p>\n

\u00a0<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n

\n
\n
\n
\n
\n
\n

Contact: Judith Sanabria Cabrera<\/span><\/p>\n

Implementation Centre: Hospital Universitario Virgen de la Victoria<\/span><\/p>\n

Research group of IBIMA involved: Independent Clinical Research and Clinical Trials Unit<\/a><\/span><\/span><\/p>\n

<\/h2>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_3″ _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_image title_text=\u00bbfondo blanco\u00bb align=\u00bbright\u00bb _builder_version=\u00bb4.27.7″ _module_preset=\u00bbdefault\u00bb transform_scale=\u00bb94%|94%\u00bb transform_translate=\u00bb-17px|100px\u00bb width=\u00bb69%\u00bb max_width=\u00bb71%\u00bb hover_enabled=\u00bb0″ global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb src=\u00bbhttps:\/\/ibima.eu\/wp-content\/uploads\/2026\/11\/fondo-blanco.png\u00bb sticky_enabled=\u00bb0″][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||-48px||false|false\u00bb custom_padding=\u00bb50px||50px||true|false\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_heading title=\u00bbAbstract\u00bb _builder_version=\u00bb4.27.7″ _module_preset=\u00bbdefault\u00bb title_font=\u00bb||||||||\u00bb title_text_color=\u00bb#0C71C3″ global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.7″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb0px||19px||false|false\u00bb hover_enabled=\u00bb0″ global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb sticky_enabled=\u00bb0″]<\/p>\n

Stroke remains a leading cause of death and a significant contributor to the global disease burden, affecting more than 840,000 people each year in the EU. SPOCK aims to improve the management of ischemic non-cardioembolic stroke and transient ischemic attack (TIA) through genotype-guided therapy. Individual genetic differences influence the effectiveness and safety of antiplatelet and statin medications, yet this variability is not taken into account in standard care.<\/p>\n

The project will conduct a multicentre randomised controlled trial to evaluate the efficacy and safety of genotype-guided antiplatelet and statin therapy compared with standard of care. The trial will enrol 2,250 patients from Finland, Sweden, Denmark and Spain, with major adverse cardiovascular events as the primary endpoint.<\/p>\n

SPOCK will also use biobank data and samples from the clinical trial to discover biomarkers that predict the response to the drugs used in patients with stroke or TIA. In addition, it will work to standardise the reporting of pharmacogenomic test results and their integration into electronic health records, informed by surveys of current practices and expert consultations.<\/p>\n

The project aims to fill critical knowledge gaps and to establish genotype-guided therapy as a new standard in stroke management, with the potential to reduce cardiovascular events and improve patient outcomes. By involving patient advocacy organisations, a clinical decision support company and healthcare professionals, SPOCK seeks to align with societal needs and strengthen the translational impact of personalised medicine in stroke care.<\/p>\n

[\/et_pb_text][et_pb_heading title=\u00bbPartners\u00bb admin_label=\u00bbT\u00edtulo\u00bb _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb title_font=\u00bb||||||||\u00bb title_text_color=\u00bb#0C71C3″ custom_margin=\u00bb30px||||false|false\u00bb hover_enabled=\u00bb0″ global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb sticky_enabled=\u00bb0″][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.7″ _module_preset=\u00bbdefault\u00bb hover_enabled=\u00bb0″ global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb sticky_enabled=\u00bb0″]<\/p>\n